Publications

5491 Results

Neoadjuvant PD-1 Blockade in Patients with Resectable Desmoplastic Melanoma (SWOG 1512)

Authors
K Kendra;J Moon;Z Eroglu;S Hu-Lieskovan;W Carson;D Wada;J Plaza;G In;A Ikeguchi;J Hyngstrom;A Brohl;B Chmielowski;N Khushalani;J Markowitz;M Monroe;K Grossmann;V Sondak;E Sharon;M Wu;A Ribas
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr 9502), abstract 9502; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), oral
Year
2022
Research Committee(s)
Melanoma
Study Number(s)
S1512

Differences in clinician and patient assessment of baseline neuropathy in patients receiving taxane-based chemotherapy enrolled to SWOG S1714 (NCT# 03939481)

Authors
M Trivedi;J Unger;D Hershman;A Darke;D Hertz;T Brannagan;SJ Smith;W Irvin;A Hathaway;A Vander Woude;V Gudena;NL Henry;M Fisch
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr 12024), poster 270; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
Year
2022
Research Committee(s)
Symptom Control and Quality of Life
Study Number(s)
S1714

A Phase II Study of Talazoparib Plus Avelumab in Patients with Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic Stk11 Genomic Alterations (SWOG S1900C, LUNG-MAP SUB-STUDY, NCT#04173507)

Authors
F Skoulidis;M Redman;J Suga;T Al Baghdadi;J Villano;S Goldberg;L Villaruz;K Minichiello;D Gandara;R Herbst;K Kelly
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr 9060), poster 48; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
Year
2022
Research Committee(s)
Lung
Study Number(s)
S1900C

Overall survival from a phase II randomized study of ramucirumab pluspembrolizumab versus standard of care for advanced non-small cell lung cancer previously treated with immunotherapy—Lung-MAP non-matched sub-studyS1800A

Authors
K Reckamp;M Redman;K Dragnev;L Villaruz;B Faller;T Al Baghdadi;S Hines;L Qian;K Minichiello;D Gandara;K Kelly;R Herbst
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr 9004), Abstract #9004; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), oral
Year
2022
Research Committee(s)
Lung
Study Number(s)
S1800A

A059102: A Randomized Phase II US Intergroup Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas

Authors
N Mehta-Shah;N Bartlett;S Barta;J Amengual;S Horwitz;B Kahl;J Friedberg;T Dockter;S Geyer;J Leonard
Journal / Conference
ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), poster session
Year
2022
Research Committee(s)
Lymphoma
Study Number(s)
CTSU/A051902

Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer (mCRC)

Authors
H Arai;Y Yang;J Millstein;Y Denda;F-S Ou;F Innocenti;H Takeda;A Doi;Y Horie;K Umemoto;N Izawa;J Wang;F Battaglin;N Kawanishi;P Jayachandran;S Soni;W Zhang;A Venook;Y Sunakawa;H-J Lenz
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr 3586), poster 380; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
Year
2022
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

Gene Expression of Vitamin D (VitD) Pathway Markers and Survival in Patients (Pts) with Metastatic Colorectal Cancer (mCRC): Findings from CALGB/SWOG 80405 (Alliance)

Authors
C Kohn;F-S Ou;C Ma;N Larson;T Zemla;C Yuan;D Niedzwiecki;B Hollis;A Nixon;H-J Lenz;CD Blanke;R Goldberg;R Mayer;A Venook;E O'Reilly;J Meyerhardt;K Ng
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr 3553), poster 347; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
Year
2022
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

Predictive value of MAOB gene expression for targeted therapy in patients (pts) with metastatic colorectal cancer (mCRC) enrolled in CALGB/SWOG 80405

Authors
W Zhang;F Battaglin;Y Yang;F-S Ou;F Innocenti;H Arai;S Soni;P Jayachandran;M Bertagnolli;H Hochster;D Niedzwiecki;R Goldberg;R Mayer;CD Blanke;A Venook;O Kabbarah;J Millstein;H-J Lenz
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr 3580), poster 374; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
Year
2022
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

E1Q11: Engendering Reproductive health in Oncologic Survivorship (EROS)

Authors
A Patel;J-W Lee;H Zaren;E Radeke;R Lerner;J Fukui;D Makower;D Tamkus;K Rosland;W Adler;A Throckmorton;S Ghamande;D Cella;MJ Fisch;L Wagner
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr 1519), poster 113; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
Year
2022
Research Committee(s)
Cancer Survivorship

Randomized phase II study of platinum and etoposide (EP) versus temozolomide and capecitabine (CAPTEM) in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine neoplasms (GEPNENs): ECOG-ACRIN EA2142

Authors
J Eads;P Catalano;G Fisher;D Rubin;A Iagaru;D Klimstra;B Konda;M Kwong;J Chan;A De Jesus-Acosta;T Halfdanarson;W Shaib;H Soares;S Hong;T Wong;P O'Dwyer
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr 4020), poster #8; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
Year
2022
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/EA2142